The erythroid leukemias

A comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease

Stuart L. Goldberg, Pierre Noel, Thomas R. Klumpp, Gordon W. Dewald

Research output: Contribution to journalArticle

Abstract

Pure erythroid malignancies, such as Di Guglielmo disease (DG), in which the predominant immature elements are proerythroblasts, are excluded from the French-American-British (FAB) classification for acute leukemia and do not fit neatly into any of the categories of myelodysplasia. This retrospective review compares the clinical and laboratory features of DG and erythroleukemia (FAB M6) among 37 cases treated at a single institution over a 7-year period. DG was defined as >30% proerythroblasts and the absence of a myeloblastic component. Clinical and laboratory features were similar in both subtypes. High proportions of secondary leukemias and prior myelodysplastic syndromes (MDS) were noted (M6, 13 of 26 cases; DG, five of 11 cases; p = 0.85). Pancytopenia was common at presentation in both groups [median white blood cells (WBC), 2,600/mm3; HgB, 8.65 gm/dl; platelets, 38.000///1]. Two-thirds of studied cases had chromosomal abnormalities typified by major karyotypic abnormalities (MAKA) involving three or more chromosomes. Abnormalities involving chromosome 5 and/or 7 occurred in 47% (48% M6 and 45% DG). Both erythroid malignancies carried a poor prognosis (M6, 6.0-month median survival; DG, 4-month survival; p = 0.74). Among those patients choosing aggressive rather than palliative therapy, higher remission rate (80 versus 25%) and survival advantage (11.5 versus 2.5 months) were seen in M6 compared to DG. However, only two long-term survivors exist. The similar clinical and laboratory features, cytogenetic patterns, and poor survival data suggest that the FAB classification schema should be modified to include DG.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalAmerican Journal of Dermatopathology
Volume21
Issue number1
StatePublished - 1999

Fingerprint

Leukemia, Erythroblastic, Acute
Leukemia
Erythroblasts
Survival
Chromosomes, Human, Pair 5
Pancytopenia
Chromosomes, Human, Pair 7
Myelodysplastic Syndromes
Palliative Care
Cytogenetics
Chromosome Aberrations
Survivors
Neoplasms
Leukocytes
Blood Platelets
Chromosomes

Keywords

  • Acute leukemia
  • Cytogenetics
  • Di Guglielmo disease
  • Erythroleukemia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dermatology

Cite this

The erythroid leukemias : A comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. / Goldberg, Stuart L.; Noel, Pierre; Klumpp, Thomas R.; Dewald, Gordon W.

In: American Journal of Dermatopathology, Vol. 21, No. 1, 1999, p. 42-47.

Research output: Contribution to journalArticle

Goldberg, Stuart L. ; Noel, Pierre ; Klumpp, Thomas R. ; Dewald, Gordon W. / The erythroid leukemias : A comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease. In: American Journal of Dermatopathology. 1999 ; Vol. 21, No. 1. pp. 42-47.
@article{1c938aa549ec41e89687e33ca6c9d12d,
title = "The erythroid leukemias: A comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease",
abstract = "Pure erythroid malignancies, such as Di Guglielmo disease (DG), in which the predominant immature elements are proerythroblasts, are excluded from the French-American-British (FAB) classification for acute leukemia and do not fit neatly into any of the categories of myelodysplasia. This retrospective review compares the clinical and laboratory features of DG and erythroleukemia (FAB M6) among 37 cases treated at a single institution over a 7-year period. DG was defined as >30{\%} proerythroblasts and the absence of a myeloblastic component. Clinical and laboratory features were similar in both subtypes. High proportions of secondary leukemias and prior myelodysplastic syndromes (MDS) were noted (M6, 13 of 26 cases; DG, five of 11 cases; p = 0.85). Pancytopenia was common at presentation in both groups [median white blood cells (WBC), 2,600/mm3; HgB, 8.65 gm/dl; platelets, 38.000///1]. Two-thirds of studied cases had chromosomal abnormalities typified by major karyotypic abnormalities (MAKA) involving three or more chromosomes. Abnormalities involving chromosome 5 and/or 7 occurred in 47{\%} (48{\%} M6 and 45{\%} DG). Both erythroid malignancies carried a poor prognosis (M6, 6.0-month median survival; DG, 4-month survival; p = 0.74). Among those patients choosing aggressive rather than palliative therapy, higher remission rate (80 versus 25{\%}) and survival advantage (11.5 versus 2.5 months) were seen in M6 compared to DG. However, only two long-term survivors exist. The similar clinical and laboratory features, cytogenetic patterns, and poor survival data suggest that the FAB classification schema should be modified to include DG.",
keywords = "Acute leukemia, Cytogenetics, Di Guglielmo disease, Erythroleukemia",
author = "Goldberg, {Stuart L.} and Pierre Noel and Klumpp, {Thomas R.} and Dewald, {Gordon W.}",
year = "1999",
language = "English (US)",
volume = "21",
pages = "42--47",
journal = "American Journal of Dermatopathology",
issn = "0193-1091",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The erythroid leukemias

T2 - A comparative study of erythroleukemia (FAB M6) and Di Guglielmo disease

AU - Goldberg, Stuart L.

AU - Noel, Pierre

AU - Klumpp, Thomas R.

AU - Dewald, Gordon W.

PY - 1999

Y1 - 1999

N2 - Pure erythroid malignancies, such as Di Guglielmo disease (DG), in which the predominant immature elements are proerythroblasts, are excluded from the French-American-British (FAB) classification for acute leukemia and do not fit neatly into any of the categories of myelodysplasia. This retrospective review compares the clinical and laboratory features of DG and erythroleukemia (FAB M6) among 37 cases treated at a single institution over a 7-year period. DG was defined as >30% proerythroblasts and the absence of a myeloblastic component. Clinical and laboratory features were similar in both subtypes. High proportions of secondary leukemias and prior myelodysplastic syndromes (MDS) were noted (M6, 13 of 26 cases; DG, five of 11 cases; p = 0.85). Pancytopenia was common at presentation in both groups [median white blood cells (WBC), 2,600/mm3; HgB, 8.65 gm/dl; platelets, 38.000///1]. Two-thirds of studied cases had chromosomal abnormalities typified by major karyotypic abnormalities (MAKA) involving three or more chromosomes. Abnormalities involving chromosome 5 and/or 7 occurred in 47% (48% M6 and 45% DG). Both erythroid malignancies carried a poor prognosis (M6, 6.0-month median survival; DG, 4-month survival; p = 0.74). Among those patients choosing aggressive rather than palliative therapy, higher remission rate (80 versus 25%) and survival advantage (11.5 versus 2.5 months) were seen in M6 compared to DG. However, only two long-term survivors exist. The similar clinical and laboratory features, cytogenetic patterns, and poor survival data suggest that the FAB classification schema should be modified to include DG.

AB - Pure erythroid malignancies, such as Di Guglielmo disease (DG), in which the predominant immature elements are proerythroblasts, are excluded from the French-American-British (FAB) classification for acute leukemia and do not fit neatly into any of the categories of myelodysplasia. This retrospective review compares the clinical and laboratory features of DG and erythroleukemia (FAB M6) among 37 cases treated at a single institution over a 7-year period. DG was defined as >30% proerythroblasts and the absence of a myeloblastic component. Clinical and laboratory features were similar in both subtypes. High proportions of secondary leukemias and prior myelodysplastic syndromes (MDS) were noted (M6, 13 of 26 cases; DG, five of 11 cases; p = 0.85). Pancytopenia was common at presentation in both groups [median white blood cells (WBC), 2,600/mm3; HgB, 8.65 gm/dl; platelets, 38.000///1]. Two-thirds of studied cases had chromosomal abnormalities typified by major karyotypic abnormalities (MAKA) involving three or more chromosomes. Abnormalities involving chromosome 5 and/or 7 occurred in 47% (48% M6 and 45% DG). Both erythroid malignancies carried a poor prognosis (M6, 6.0-month median survival; DG, 4-month survival; p = 0.74). Among those patients choosing aggressive rather than palliative therapy, higher remission rate (80 versus 25%) and survival advantage (11.5 versus 2.5 months) were seen in M6 compared to DG. However, only two long-term survivors exist. The similar clinical and laboratory features, cytogenetic patterns, and poor survival data suggest that the FAB classification schema should be modified to include DG.

KW - Acute leukemia

KW - Cytogenetics

KW - Di Guglielmo disease

KW - Erythroleukemia

UR - http://www.scopus.com/inward/record.url?scp=33646898454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646898454&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 42

EP - 47

JO - American Journal of Dermatopathology

JF - American Journal of Dermatopathology

SN - 0193-1091

IS - 1

ER -